CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

Pain Management, published by Future Medicine Ltd, is a premier journal that serves the fields of anesthesiology, pain medicine, and dentistry. With its ISSN 1758-1869 and E-ISSN 1758-1877, this journal is committed to advancing knowledge and practice through high-quality research articles, clinical studies, and expert reviews. The journal has established itself as a pivotal resource in pain management with a commendable impact factor and recognition in category quartiles, achieving Q2 rankings in Anesthesiology and Pain Medicine, as well as in miscellaneous Medicine and Dentistry categories as of 2023. Researchers and professionals will find a wealth of information in its comprehensive articles, which are essential for staying at the forefront of developments in pain management therapies and techniques. Although access is not open, the journal is recognized for its rigor and significance in shaping the future of pain management practices globally. Join the community of experts engaging in cutting-edge discussions by exploring the impactful research being published in this essential resource.

American Journal of Cardiovascular Drugs, published by ADIS INT LTD, is a premier peer-reviewed journal dedicated to the field of cardiology and cardiovascular medicine. With an ISSN of 1175-3277 and an E-ISSN of 1179-187X, this esteemed journal has established itself as a crucial platform for disseminating high-quality research since its inception in 2001. It holds a significant position in its domain, ranking in the second quartile (Q2) across several categories including Cardiology, Medicine (miscellaneous), and Pharmacology (medical) for the year 2023. With its Scopus ranks placing it in the 81st percentile for Cardiology and 77th percentile for Pharmacology, the journal is highly regarded among professionals, researchers, and students alike. While it is not an open-access journal, its comprehensive articles and systematic reviews provide an in-depth exploration of cardiovascular drug therapy, therapeutic advancements, and clinical practices, making it an invaluable resource for anyone invested in the future of cardiovascular health.

Current Reviews in Clinical and Experimental Pharmacology is a cutting-edge journal published by Bentham Science Publishers in the United Arab Emirates, focusing on the dynamic field of pharmacology. With an ISSN of 2772-4328 and an E-ISSN of 2772-4336, this journal has rapidly established itself as a significant resource for researchers and professionals in the medical and pharmaceutical sciences since its inception in 2021. It boasts an impressive Q3 ranking in Pharmacology (medical) and Q2 in the Pharmacology, Toxicology and Pharmaceutics (miscellaneous) category as of 2023. Furthermore, it ranks #14/80 in general pharmacology, reflecting its esteemed position within the scientific community. As an Open Access publication, it ensures that groundbreaking research is readily accessible, fostering collaboration and innovation. The journal invites high-quality reviews and original articles that address contemporary issues and advancements in clinical and experimental pharmacology, making it an essential venue for disseminating knowledge and engaging with emerging trends in therapeutic developments.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, published by SAGE PUBLICATIONS LTD, is a pivotal resource in the fields of oncology, pharmacology, and medicine, with a dedicated focus on the evolving discipline of oncology pharmacy. Based in the United Kingdom, this journal has been diligently serving its readers since 1995 and continues to explore the intersection of pharmaceutical care and cancer treatment, showcasing innovative practices, research findings, and clinical advancements that are indispensable for healthcare professionals, researchers, and students alike. Although not an open-access journal, it holds a respectable Category Quartile Q3 ranking across its various fields, including Medicine, Oncology, and Pharmacology, indicating its relevance in nurturing academic discourse and addressing critical issues in cancer care. With an ISSN of 1078-1552 and E-ISSN of 1477-092X, the journal invites contributions that enhance the understanding of pharmaceutical interventions in oncology, aiming to improve therapeutic outcomes and patient care. Join a global community of professionals committed to excellence in oncology pharmacy practice and stay informed with cutting-edge research and reviews that significantly impact patient healthcare strategies.

PHARMACOTHERAPY, an esteemed journal published by WILEY, stands as a pivotal resource within the field of medical pharmacology. With its ISSN 0277-0008 and E-ISSN 1875-9114, this journal has been at the forefront of pharmacological research since its inception in 1981. Renowned for its rigorous peer-review process and impactful contributions, it currently holds a prestigious Q1 quartile ranking in the pharmacology category, underscoring its significance as a leading publication in the field. It ranks #40 out of 272 journals in Scopus, placing it in the top 15% percentile of its category. While not an open-access publication, PHARMACOTHERAPY remains committed to advancing knowledge and understanding in pharmacological sciences, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to improving therapeutic outcomes and drug utilization. Based in the United States, at 111 River St, Hoboken, NJ, the journal is poised to continue its impact through to 2024 and beyond, welcoming contributions that further the discourse in pharmacotherapy.

Current Drug Therapy is a pivotal journal in the field of pharmacology, published by Bentham Science Publishers Ltd. based in the United Arab Emirates. With an ISSN of 1574-8855 and an E-ISSN of 2212-3903, this journal serves as a vital platform for disseminating scholarly works that focus on the latest advancements and therapeutic applications within drug therapy. Operating without Open Access, it consistently attracts a diverse readership including researchers, healthcare professionals, and students eager to explore comprehensive reviews, original research articles, and critical insights into current trends and technologies from 2007 to 2024. Maintaining a steady presence in the competitive landscape, the journal's category quartiles reflect its growing significance, with rankings of Q4 in Pharmacology (medical) and Q3 in the broader scopes of Pharmacology, Toxicology, and Pharmaceutics as of 2023. Its contribution to the discourse in the domains of General Pharmacology, Toxicology and Pharmaceutics is underscored by its Scopus rank of #54 out of 80 in its category. Current Drug Therapy is not merely an academic resource; it is a beacon for innovation and a forum for critical dialogue that fosters the exchange of cutting-edge ideas in medication therapy, making it an essential read for professionals at the forefront of pharmaceutical Sciences.

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.

Rational Pharmacotherapy in Cardiology, published by the SOC CARDIOLOGY RUSSIAN FEDERATION, stands as a crucial platform for advancing knowledge in the field of cardiology and pharmacology. Established as an Open Access journal in 2005, it allows for unrestricted access to research findings, fostering collaboration among researchers, clinicians, and students. The journal, with its ISSN 1819-6446 and E-ISSN 2225-3653, focuses on the intersection of rational pharmacotherapy and cardiovascular medicine, aiming to enhance treatment strategies and patient outcomes through evidence-based studies. Though currently positioned in the Q4 category in both cardiology and pharmacology rankings, its ongoing commitment to rigorous peer review and scholarly research ensures its relevance and growth in the scientific community. With a unique address in Moscow, Russia, the journal seeks to serve as a valuable resource for those dedicated to improving cardiovascular health and therapeutic practices worldwide, making it an essential read for professionals keen on the latest trends and discoveries in this vital area of medicine.

Journal of Pharmacology & Pharmacotherapeutics is a vital academic resource published by SAGE Publications Inc., focusing on the diverse and evolving fields of pharmacology and pharmacotherapy. With an ISSN of 0976-500X and E-ISSN 0976-5018, this journal serves as a platform for rigorous research and innovative insights from 2010 to 2024, reflecting the latest advancements and challenges within the pharmacological landscape. Despite being placed in the Q4 quartile for both general pharmacology and medical pharmacology in 2023, it continues to be an essential resource for researchers, professionals, and students striving to understand the complexities of drug action, therapy optimization, and pharmaceutical sciences. The journal underscores the importance of disseminating critical findings to stimulate further research and collaborative dialogue. Although currently not open access, it can be accessed through leading academic databases, positioning itself as a significant entity in the medical and pharmacological research community.